NEW YORK, March 23, 2015 /PRNewswire/ -- Summary

GlobalData's clinical trial report, "End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" provides data on the End-Stage Kidney Disease (end-stage renal disease or ESRD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating End-Stage Kidney Disease (end-stage renal disease or ESRD). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Read the full report: http://www.reportlinker.com/p02796430-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/end-stage-kidney-disease-end-stage-renal-disease-or-esrd-global-clinical-trials-review-h1-2015-300054639.html

SOURCE Reportlinker

...

The National Renal Administrators Association and Renal Physicians Association will host a workshop for dialysis facility medical directors Oct. 9-10 in Orlando. 

The workshop will feature nephrology experts discussing the following topics:

• Trends and opportunities in patient care
• Understanding facility performance scores such as QIP and the 5-Star Program
• Opportunities for quality improvement in infection control
• Innovations in home therapy

"The majority of RPA's members serve as dialysis facility medical directors," said Dr. Rebecca Schmidt, RPA president. "We have developed numerous educational tools and programs to assist medical directors with fulfilling their roles. This workshop provides an additional opportunity to reach medical directors and facility administrators with valuable information to improve care delivery in dialysis facilities."

The Dialysis Facility Medical Directors Symposium is a part of the 2015 NRAA Annual Fall Conference hosted at the Hilton Orlando Lake Buena Vista on Oct. 7–10.

"The NRAA and the RPA have worked for more than 35 years in the industry," said Marc Chow, NRAA executive director. "This collaborative effort between both associations combines forces in order to develop ways to progress patient care for the 600,000 people on dialysis due to chronic kidney disease."

CMEs will be offered during the workshops for physicians seeking to maintain licensure and certification.

Registration opens in June.

...

From Staff Reports

In recognition of National Kidney Month during March, Fresenius Medical Care North America (FMCNA) has invited the community to attend its “Healthy Lifestyle Day” on Thursday, March 26 at its Fresenius Medical Care Discovery clinic in Huntsville.

FMCNA, the nation’s leading dialysis provider, is hosting a series of wellness events throughout the month in select clinics nationwide to raise awareness of kidney disease for those who might be at risk, and to emphasize to people with kidney disease or on dialysis the importance of eating well and staying physically active.

FMCNA experts will offer wellness tools, tips and recipes, plus kidney screenings and information about treatment options for those with kidney failure.

 Dietitians and social workers will be on hand to discuss how people can live better lives on dialysis by becoming more physically active and eating healthier foods

There will be light refreshments, educational materials including tips and recipes, free kidney disease risk-assessment screenings. Nurses and staff available to discuss patient services and the latest dialysis treatment options, including home dialysis and in-center nighttime dialysis.

The staff will host one of the company’s informative Treatment Options Programs (TOPs) to educate at-risk patients and their families about chronic kidney disease and how to choose treatments for kidney failure that best suit their health and lifestyle needs.

 The clinic is located at 1131 Eagletree Lane Southwest, Suite 100 in Huntsville. There is no cost to attend. For more information, contact Cynthia Church at 256-489-4160.

...

Calcification in the media of arteries may be a useful measure for screening.

Vascular calcification (VC) is highly prevalent in non-dialysis patients with chronic kidney disease (CKD)—and a certain type, medial calcification, might be deadly.

A new study finds that 79% of patients have VC and in 47% it is prominent. In particular, VC occurring in the medial portion of muscular arteries was associated with twice the risk of all-cause mortality and 3.5 times the risk of cardiovascular mortality. VC did not predict CKD progression.

“Our data suggest that the presence of VC assessed by radiographs of the hand and pelvis is an independent and robust predictor of all-cause and cardiovascular mortality and the period of hospitalization in patients with non-dialysis CKD, supporting the KDIGO [Kidney Disease Improving Global Outcomes] guidelines on the use of simple radiology for screening VC in patients with CKD,” researchers led by José L. Górriz, MD, of Hospital Universitario Dr. Peret in Valencia, Spain, wrote in a paper published online ahead of print in the Clinical Journal of the American Society of Nephrology.

The association between VC and the risk of morbidity and mortality is a common finding in patients on dialysis, the researchers noted. Their data showed that this association begins at earlier stages of CKD, they stated.

For this analysis of the Study of Mineral and Bone Disorders in CKD, the researchers studied VC in 742 patients with non-dialysis CKD stages 3–5 from 39 Spanish centers followed from 2009–2012. The investigators evaluated two measures of VC: the Adragao score (based on x-rays of the hands and pelvis) and Kauppila score (based on x-rays of the lumbar spine). 

Only an Adragao score 3 or greater was independently associated with all-cause and cardiovascular mortality as well as shorter hospitalization-free periods. The Adragao score reflects VC in muscular arteries, which are more susceptible to calcification of the media. (Kauppila score by comparison identifies calcification of the intima in elastic arteries, which appears to be partly age-related.)

In an editorial accompanying the new study, Wei Chen, MD, and Michel L. Melamed, MD, of Albert Einstein College of Medicine in Bronx, N.Y., noted that the study “importantly shows that VC starts earlier in the course of CKD, which suggests that it may be potentially modifiable long before the initiation of dialysis.”

Cardiovascular mortality is unacceptably high in CKD patients, and VC likely plays a large role either as the cause or as the marker of this mortality, they stated.

“The results suggest that medial calcification may have a greater prognostic power and may be a useful index to identify patients with CKD who are at higher risk of death and hospitalizations,” the editorialists stated.

Medial calcification is associated with arterial stiffness, systolic hypertension, and left ventricular hypertrophy. Future studies should assess the prognostic value of various available imaging tools, they noted.  

“The findings also support the search for possible modifiable factors in the pathogenesis of VC including the role of serum phosphate, phosphate binders, vitamin D, and other CKD-mineral and bone disorder markers that were not fully evaluated in the study,” Drs. Chen and Melamed wrote.

Sources

1. Gorriz, JL, et al. Clinical Journal of the American Society of Nephrology, 2015; doi: 10.2215/CJN.07450714.
   
2. Wei Chen and Michal L. Melamed. Vascular Calcification in Predialysis CKD: Common and Deadly; published ahead of print by Clinical Journal of the American Society of Nephrology, March 13, 2015; doi:10.2215/CJN.01940215.

...